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Abstract
Context: Whether androgen deprivation therapy (ADT) for men with prostate cancer
(PCa) increases the risk of cardiovascular disease (CVD) remains controversial. Pooled
analyses using data from randomised controlled trials suggest no increased risk of fatal
CVD following ADT, but no pooled analyses exist for observational studies.
Objective: To perform a meta-analysis using observational data on ADT and risk of CVD
events in men with PCa.
Evidence acquisition: PubMed and Embase were searched using predeﬁned inclusion
criteria to performmeta-analyses on associations between types of ADT and nonfatal and
fatal CVD outcomes using information from observational studies. Random effects meta-
analyseswereconducted toestimate relative risks (RRs) and95%conﬁdence intervals (CIs).
Evidence synthesis: A total of eight observational studies were identiﬁed studying at
least one type of ADT and a nonfatal or fatal CVD outcome. The RR for risk of any type of
nonfatal CVD was 1.38 (95% CI, 1.29–1.48) for men with PCa on gonadotropin-releasing
hormone (GnRH) agonists, compared with men not treated with ADT. When analysing
nonfatal ischemic heart disease only, the RR was 1.39 (95% CI, 1.26–1.54). The associa-
tions between GnRH agonists and nonfatal or fatal myocardial infarction or stroke were
even stronger: RR: 1.57 (95% CI, 1.26–1.94) and RR: 1.51 (95% CI, 1.24–1.84), respectively.
The results for other types of ADT in relation to the risk of any nonfatal CVDwere RR: 1.44
(95% CI, 1.28–1.62) for orchiectomy and RR: 1.21 (95% CI, 1.07–1.367) for antiandrogens.
Conclusions: Observational data show a consistent positive association between ADT
and the risk of CVD. This ﬁnding supports the need for future randomised trials of PCa
patients that include older patients andmenwithmultiple comorbidities to better reﬂect
the general population.
Patient summary: We investigated all the available data from observational studies on
hormonal treatment for prostate cancer and its possible cardiovascular adverse effects.
We found consistent evidence that this treatmentmay increase the risk of cardiovascular
disease.
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Androgen deprivation therapy (ADT) is the mainstay
treatment for advanced prostate cancer (PCa). Since its
discovery in1941 [1], different types of treatments to impede
androgen tumour growth stimulation have been developed
including gonadotropin-releasing hormone (GnRH) agonists
(ie, buserelin, goserelin, leuprorelin, and triptorelin), orchi-
ectomy, GnRH antagonists (ie, abarelix, degarelix), oestro-
gens (diethylstilbestrol), and antiandrogens (cyproterone
acetate, nilutamide, flutamide, and bicalutamide) [2]. For
locally advanced andmetastatic PCa, ADT has been shown to
improve survival rates, palliate symptoms effectively, and
delay cancer progression [3]. Men on ADTmay remain under
treatment for prolonged periods of time [4]; thus adverse
effects are important to consider when making treatment
decisions. Reported adverse effects include hot flashes,
erectile dysfunction, loss of libido, bone fractures, obesity
and sarcopaenia, lipid alterations and insulin resistance,
metabolic syndrome, diabetes, and cardiovascular disease
(CVD) [5].
Several recent meta-analyses have focused on ADT-
related cardiovascular (CV) morbidity and mortality using
data from randomised controlled trials (RCTs) with
different primary end points. No association was found
for CV mortality; however, investigators were not able
to stratify by baseline cardiac comorbidity [6]. Together
with a large retrospective study [7], some very recent data
[8] suggest that ADT is associated with increasedmortality
(especially cardiac-specific mortality) only amongst men
with a history of cardiac disease (eg, congestive heart
failure or myocardial infarction [MI]). In addition, a meta-
analysis by Albertsen et al, based on six RCTs comparing
treatment efficacy of GnRH agonists versus antagonist,
showed that the risk of nonfatal CVD and all-cause
mortality was particularly high in men with preexisting
CVD. This risk was also observed to be higher for those
treated with GnRH agonists rather than GnRH antagonists
[9].
As a result of the increasing number of studies finding a
positive association between ADT and CVD, the European
Association of Urology’s 2012 PCa guidelines comment on
the association of ADT with nonfatal CVD but state that the
evidence regarding ADT and CVD mortality risk is not
consistent [5]. Several large observational studies have
identified an association between ADT and CVD [10–17]
including some studies that examined both nonfatal and
fatal CVD. RCTs provide the highest grade of evidence for the
assessment of the effectiveness of treatments [18]. None-
theless, these trials tend to exclude older patients or those
with a higher number of comorbidities [19]. For instance, in
the meta-analysis on RCTs by Nguyen et al, authors
highlight that given that they analysed phase 3 RCTs, it is
likely that participants had fewer comorbidities than the
general population, making them less susceptible to ADT-
related CV adverse effects [6].
The RCTs of ADT were not designed to ascertain CV
outcomes other than death. Observational studies, when
well conducted, have been shown to provide similarestimate effects to RCTs. Elderly participants and those
with comorbidities, two common characteristics of PCa
patients receiving ADT, do not need to be excluded
[20]. Including these men in the study population will
provide results that are more applicable to the general
population of interest. Finally, observational studies also
allowed examination of CV outcomes other than death.
Therefore, we performed the first meta-analysis on
ADT and risk of fatal and nonfatal CVD using data from
observational studies. This study is novel because it
specifically focuses on observational studies to address
some of the limitations of RCTs as previously described
(ie, selection of healthier population and a focus on CVD
mortality only).
2. Evidence acquisition
2.1. Literature search strategy
We used computerised literature search databases
(PubMed search followed by Embase) to identify full texts
and abstracts published as of June 15, 2014. Our searches
included cardiovascular diseases as search/Medical Subject
Heading (MeSH) terms for the outcome variable of interest.
In addition, prostatic neoplasms and androgen deprivation
therapy, antineoplastic agents hormonal/adverse effects or
endocrine treatmentwere used as search/MeSH terms for the
exposure variable of interest. Our search strategy was
limited to publications with a focus on humans. By not
restricting the search to research papers, we made it
possible to include grey literature, such as letters and
abstracts presented at relevant conference meetings, to
address the effects of ADT on CV morbidity and mortality.
All references of selected articles were checked, including
hand searches, which is an effective practical way to cross-
check the completeness of the electronic searches.
2.2. Inclusion criteria
The selected articles were chosen based on the following
inclusion criteria: the publication pertained to an epide-
miological observational study that measured exposure
to ADT, the comparison group was clearly defined, CVD
(fatal or nonfatal) was assessed as an outcome, CVD events
were clearly defined, the study focused on men with
PCa and disease stage was clearly described, and ADT type
was specified. Titles of articles were first reviewed to
ascertain whether they might potentially fit the inclusion
criteria. After assessing the abstract, a more thorough
subsequent assessment was performed when there was
doubt whether the paper would fit the inclusion criteria.
The list of potential articles was further shortened by
performing evaluations of the methods and results of
each remaining paper. Figure 1 provides detailed infor-
mation regarding the progressive flowof the study exclusion
process. Figure 2 shows how the Strengthening the Repor-
ting of Observational Studies in Epidemiology (STROBE)
criteria were also used to evaluate the quality of included
studies [21].
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PubMed search 1
Cardiovascular diseases [MeSH] AND prostac neoplasms [MeSH] AND androgen deprivaon therapy
108 results
Embase search 
279 results
PubMed search 2
Anneoplasc agents, 
hormonal/adverse eﬀects 
[MAJR]
52 results
PubMed search 3
Endocrine treatment
60 results
8 included
(plus 1 erratum)
Hand searches
3 addional studies 19 excluded:
CVD not outcome: 2
No data available: 2
Unspeciﬁed ADT: 6
Duplicaon of data: 2 
RCT: 7
25 potenally relevant
Fig. 1 – Flowchart of study selection procedure.
ADT = androgen deprivation therapy; CVD = cardiovascular disease; MeSH = Medical Subject Heading; RCT = randomised controlled trial.
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For each study, we considered author, year of publication,
ADT type and exposure (binary), study type (case control or
cohort), outcome, and number of cases and total subjects for
each level of ADT. The outcome was defined as fatal or
nonfatal CVD based on the CVD definition provided by the
World Health Organisation [22]: coronary heart disease
(CHD), ischemic heart disease (IHD), acute MI, arrhythmia,
sudden cardiac death, peripheral artery disease, deep vein
thrombosis (DVT), pulmonary embolism (PE) and arterial
embolism, and stroke and transient ischemic attack.
However, it is arguable whether thromboembolic disease
(TED) should be included because from an aetiological point
these may differ from CV outcomes such as MI and stroke.
It is known that recent surgery as well as PCa disease
progression may also be linked to the risk of TED
[11]. Therefore, we also performed a sensitivity analysis
excluding those studies where DVT or PE was the main
outcome. Heart failure was not included as an outcome due
to its wide range of clinical aetiologies. First, we assessed
the risk of any nonfatal CVD event. When a distinction
between a fatal and nonfatal CVD event was not made, the
study was included and the events were considered
nonfatal. However, an additional sensitivity analysis was
performed including only the five studies explicitly
specifying nonfatal events. Next, we focused specifically
on nonfatal IHD to further disentangle the possible
associations with ADT. Lastly, we investigated the associa-
tion between ADT and MI and stroke. For the latter, we didnot make a distinction between nonfatal and fatal because
these are thought be equally relevant clinically.
2.4. Statistical methods
The effect of ADT compared with no ADT on the risk of CVD
amongst men with PCa was evaluated by calculating the
random effects summary relative risk (RR). Forest plots
were created to display the RR estimates for each study.
Potential heterogeneity of the study results was evaluated
using the I2 statistic as well as a ‘‘remove-one’’ analysis.
Potential publication bias was assessed with a contour-
enhanced funnel plot [23] and by conducting the Egger test
[24]. ADT was grouped into different types of treatment:
GnRH agonists, orchiectomy, and antiandrogens (no studies
of GnRH antagonists were identified).
Because our analyses did not allow for adjustment, we
examined the robustness of estimated treatment effects to
potential observed and unobserved confounders [25–27].
To do this, we assumed there was a confounder such as
diabetes (observed) or smoking (unobserved), associated
with both intake of ADT and development of nonfatal CVD
(our outcome with the lowest risk ratio). We then
reestimated the effect of ADT on CVD after adjusting for
these additional variables under specific assumptions
regarding the prevalence of the confounder in men who
were on ADT and those who were not as well as the
confounder’s relationship with the outcome. For age,
existing evidence suggests that men with diabetes have
twice the risk of CVD as men without diabetes [28]. In one
[(Fig._2)TD$FIG]
Article Section     STROBE key points for observational studies assessment 
Keating 
SEER
Keating 
Veterans
Van Hemelrijck 
DVT PE
Van Hemelrijck 
CVD
Azoulay Hu Jespersen
Martin 
Merino
Title and abstract 1
Indicate the study’s design with a commonly used term in 
the title or the abstract
Provide in the abstract an informative and balanced 
summary of what was done and what was found
Introduction
Background/rationale 2
Explain the scientific background and rationale for the 
investigation being reported
Objectives 3
State specific objectives, including any prespecified 
hypotheses
Methods
Study design 4 Present key elements of study design early in the paper
Setting 5
Describe the setting, locations, and relevant dates, including 
periods of recruitment, exposure, follow-up, and data 
collection
Participants 6
Cohort study—Give the eligibility criteria, and the sources 
and methods of selection of participants. Describe methods 
of follow-up 
Case-control study—Give the eligibility criteria, and the 
sources and methods of case ascertainment and control 
selection. Give the rationale for the choice of cases and 
controls 
Cross-sectional study—Give the eligibility criteria, and the 
sources and methods of selection of participants
Variables 7
Clearly define all outcomes, exposures, predictors, potential 
confounders, and effect modifiers. Give diagnostic criteria, 
if applicable
Data sources/ 
measurement
8
 For each variable of interest, give sources of data and 
details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than 
one group
Bias 9 Describe any efforts to address potential sources of bias
Study size 10 Explain how the study size was arrived at
Quantitative variables 11
Explain how quantitative variables were handled in the 
analyses. If applicable, describe which groupings were 
chosen and why
Statistical methods 12
Describe all statistical methods, including those used to 
control for confounding
Describe any methods used to examine subgroups and 
interactions
Explain how missing data were addressed
Cohort study—If applicable, explain how loss to follow-up 
was addressed 
Case-control study—If applicable, explain how matching of 
cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical 
methods taking account of sampling strategy
Describe any sensitivity analyses
Results
Participants 13
Report numbers of individuals at each stage of study—eg 
numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing 
follow-up, and analysed
Give reasons for non-participation at each stage
Consider use of a flow diagram
Descriptive data 14
Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders
Indicate number of participants with missing data for each 
variable of interest
Cohort study—Summarise follow-up time (eg, average and 
total amount)
Outcome data 15
Cohort study—Report numbers of outcome events or 
summary measures over time
Case-control study—Report numbers in each exposure 
category, or summary measures of exposure
Cross-sectional study—Report numbers of outcome events 
or summary measures
Main results 16
Give unadjusted estimates and, if applicable, confounder-
adjusted estimates and their precision (eg, 95% confidence 
interval). Make clear which confounders were adjusted for 
and why they were included
If relevant, consider translating estimates of relative risk 
into absolute risk for a meaningful time period
Other analyses 17
Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses
Discussion
Key results 18 Summarise key results with reference to study objectives
Limitations 19
Discuss limitations of the study, taking into account sources 
of potential bias or imprecision. Discuss both direction and 
magnitude of any potential bias
Interpretation 20
Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from 
similar studies, and other relevant evidence
Generalisability 21
Discuss the generalisability (external validity) of the study 
results
Other information
Funding 22
Give the source of funding and the role of the funders for 
the present study and, if applicable, for the original study on 
which the present article is based
Fig. 2 – Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for observational studies included in our meta-
analyses.
CVD = cardiovascular disease; DVT = deep vein thrombosis; PE = pulmonary embolism.
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E U RO P E AN URO LOG Y 6 8 ( 2 0 1 5 ) 3 8 6 – 3 9 6390study, the observed prevalence of diabetes was 12% in men
on ADT and 11% in men not on ADT [12], although other
evidence suggests rates of diagnosed diabetes in the United
States of approximately 20% [29]. We assumed rates of
diabetes were 15% for men not on ADT and 30% for men on
ADT. For smoking, prior evidence suggests that smoking
increases the risk of CVD approximately 2.5-fold [30]. Over-
all, about 20% of adult men in the United States smoke
[31]. We assumed that smoking rates in men not on ADT
were 15% and in men on ADT were 30%.
To further identify possible sources of heterogeneity
across different subgroups/patient population, we per-
formed subgroup analyses by publication year and region
for the meta-analysis focused on GnRH agonists and any
type of nonfatal CVD. All analyses were performed using
Stata software v. 12.
3. Evidence synthesis
The initial search for ADT and fatal and nonfatal CVD
resulted in 108 articles via PubMed and 279 via Embase.
After extracting information from the abstracts, 25 articles
were selected for further investigation (Fig. 1). Three
additional studies were identified via hand searches.
Finally, eight studies that included different types of ADT
and CVD outcomes were selected for the primary data
analysis (Table 1). Based on the previously defined inclusion
criteria, we excluded 19 studies. Amongst these, two did not
have CVD as an outcome, two were excluded due to lack of
data, six did not specify the type of ADT, seven were RCTs,
and two had analysed the same data as studies that were
already included in this meta-analysis [14,32–49]. One
additional publication, an erratum for an already included
study, was also included [50].
The random effects analysis evaluating GnRH agonists
and the risk of any type of CVD indicated a RR of 1.38 (95%
confidence interval [CI], 1.29–1.48) for men with PCa who
were treated versus men who were not treated with ADT
(Fig. 3a). The I2 statistic suggested heterogeneity (I2 = 85%),
even though every individual estimate indicated a positive
association. The ‘‘remove-one’’ analysis did not indicate
major influences of one specific study. Both the pooled RR
and the I2 did not alter dramatically upon removal of any of
the included studies (results not shown). Next we analysed
GnRH agonists and nonfatal IHD only, which resulted in
an RR of 1.39 (95% CI, 1.26–1.54). To address potential
heterogeneity in outcome, we also excluded both studies by
Keating et al [12,13] and the study by Jespersen et al (15)
because these analysed the risk of fatal or nonfatal CVD
combined. However, the results were similar to the findings
cited earlier: RR of 1.38 (95% CI, 1.27–1.50). For nonfatal
IHD, the results did not change upon exclusion of these
studies: RR was 1.44 (95% CI, 1.36–1.54).
When assessing publication bias, the funnel plot showed
an area where missing studies are perceived that includes
regions of both low and high statistical significance,
suggesting that both studies that showed ADT to be
nonsignificantly and significantly inversely associated with
CVD were missing (Fig. 3b). Therefore, publication biascannotbeacceptedas theonlycauseof funnel asymmetry if it
is believed that studies are being suppressed because of a
mechanism based on two-sided p values. The Egger test
showed an estimated bias coefficient of 2.72, with a
standard error of 7.12, givingap value of 0.7. The test thusdid
not provide evidence for the presence of small-study effects.
Subgroup analyses by publication year and region for the
meta-analysis of GnRH agonists and any type of nonfatal
CVD showed the following results. Studies published before
2010 showed an RR of 1.31 (95% CI, 1.20–1.41) and those
from 2010 onwards had an RR of 1.44 (95% CI, 1.30–1.59).
Studies conducted in the United States resulted in an RR of
1.41 (95% CI, 1.27–1.56), whereas those published in Europe
resulted in an RR of 1.36 (95% CI, 1.23–1.51).
In analyses assessing the sensitivity of our findings to
confounders, we first considered differences in diabetes.We
assumed that rates of diabeteswere two times higher inmen
on ADT (30%) than men not on ADT (15%). In this case, the
association between ADT and risk of CVD would be
statistically significant (RR: 1.22; 95% CI, 1.14–1.31). Even
if rates of diabetes were three times higher (45% vs 15%), the
difference would still be statistically significant (RR: 1.09;
95% CI, 1.02–1.17).We also considered a confounder, such as
smoking status, and assumed that the prevalence of smoking
was twotimeshigher inmenonADT(30%) than inmennoton
ADT (15%). If 30% of men on ADT smoked, the association
between ADT and risk of CVD would still be statistically
significant (RR: 1.26; 95% CI, 1.18–1.36). However, if the rate
of smoking amongst men on ADT was three times higher
(45%), this association would no longer be statistically
significant (RR: 1.01; 95% CI, 0.94–1.08).
We performed a sensitivity analysis excluding those
studieswhere DVT and PEwere themain outcome, but again
the results did not alter: RRwas 1.36 (95%CI, 1.27–1.47)with
I2 = 84%.
The results for other types of ADT in relation to risk of
any nonfatal CVD were RR of 1.44 (95%, 1.28–1.62) for
orchiectomy and 1.21 (95% CI, 1.07–1.367) for antiandro-
gens (Fig. 3c and 3d). Exclusion of those studies not making
a distinction between fatal or nonfatal outcome again
resulted in similar findings: RR was 1.38 (95% CI, 1.20–1.57)
and 1.12 (95% CI, 1.04–1.21), respectively. The associations
between GnRH agonists and nonfatal or fatal MI or stroke
were even stronger: RR was 1.57 (95% CI, 1.26–1.94) and
1.51 (95% CI, 1.24–1.84), respectively (Figs. 4 and 5).
3.1. Discussion
In this first meta-analysis evaluating observational studies
for the association between ADT and CVD, we found that
GnRH agonists were associated with a 38% increased risk of
any type of nonfatal CVD compared with men with PCa not
treated with ADT. For orchiectomy and antiandrogens, this
increase was 44% and 21%, respectively. The associations
between GnRH agonists and nonfatal or fatal MI or stroke
were even stronger: 57% and 51%, respectively.
CV morbidity and mortality as a consequence of ADT in
men with PCa have been the subject of several systematic
reviews and meta-analyses of RCTs [6,49]. A recent pooled
Table 1 – Description of all eight studies included in our meta-analysis using observational data for the association between androgen deprivation therapy and cardiovascular disease
Study Database Year Study type ADT type No. of patients Age
distribution, yr
Outcome: no. of events/no. exposed
(no. of events/no. unexposed)
Main ﬁnding
Azoulay
et al [14]
UKGPRD 2011 Case control GnRH agonists,
orchiectomy,
antiandrogens combined
androgen blockade,
medical or surgical ADT
7986 men
with PCa
78.5 (mean) Nonfatal stroke: 453/4026 (361/3960) Compared with nonusers of ADT,
current users of GnRH agonists, oral
antiandrogens, bilateral orchiectomy
increased risk of stroke/TIA
Hu et al [16] SEER 2012 Prospective
cohort
GnRH agonists,
orchiectomy
182 757 men with
nonmetastatic PCa
66–69, 70–74,
75–79, 80–84,
>85
Nonfatal peripheral arterial disease:
2773/91 379 (1919/91 379)
Venous thromboembolism: 1227/91 379
(950/91 379)
GnRH agonists and orchiectomy are
associated with an increased risk of
peripheral artery disease and venous
thromboembolism
Keating
et al [12]
SEER 2006 Prospective
cohort
GnRH agonists,
orchiectomy
73 196 men with
locoregional PCa
66–69, 70–74,
75–79, 80–84,
>85
Nonfatal/fatal CHD: 2241/31 621
(2549/41 575)
Nonfatal/fatal MI: 425/31 621
(453/41 575)
GnRH agonists associated with
increased risk of incident diabetes,
CHD MI, and sudden cardiac death
Keating
et al [13]
US VHA 2010 Prospective
cohort
GnRH agonists,
orchiectomy,
antiandrogens, combined
androgen blockade
37 443 men with
PCa
<55, 56–60,
61–65, 66–70,
71–75, >75
Nonfatal/fatal CHD:
705/14 563 (712/23 964)
Nonfatal/fatal MI: 183/14 563
(177/23 964)
Nonfatal/fatal stroke: 274/14 563
(271/23 964)
GnRH agonist associated with
increased risk of incident CHD MI,
sudden cardiac death. Combined
androgen blockade associated with
an increased risk of incident CHD.
Orchiectomy associated with CHD
and MI
Jespersen
et al [15]
Danish
Cancer
Registry
2014 Prospective
cohort
GnRH agonists,
orchiectomy
31 571 men with
PCa
30–59, 60–69,
70–79, 80
Nonfatal/fatal MI: 164/11 264
(223/20 307)
Nonfatal/fatal stroke: 188/11 264
(244/20 307)
GnRH agonists associated with
increased risk of MI and stroke
Martı´n-Merino
et al [17]
UKGPRD 2011 Prospective
cohort
GnRH agonists,
orchiectomy,
antiandrogens, combined
androgen blockade
5103 men with PCa 51–69, 70–84 Nonfatal MI: 198/1455 (199/1709) Combination therapy with GnRH
agonists and antiandrogens
associated with signiﬁcant increases
in the risk of CHD, AMI, incident HF,
and hospitalized HF
Van
Hemelrijck
et al [10]
PcBaSE
Sweden
2010 Prospective
cohort
GnRH agonists,
orchiectomy,
antiandrogens, combined
androgen blockade,
medical or surgical ADT
76 601 men with
PCa
<65, 65–74, 75 Fatal MI: 749/17 797 (139/45 058)
Fatal IHD: 1309/17 797 (1591/45 958)
Fatal arrhythmia: 115/17 707
(139/45 958)
Fatal stroke: 335/17 797 (426/45 958)
Nonfatal MI: 1293/17 797 (2252/45 958)
Nonfatal arrhythmia: 1000/17 797
(2287/45 958)
Nonfatal stroke: 1551/17 797
(2958/45 958)
Nonfatal IHD: 2020/17 797 (3945/45 958)
Increased relative risks of nonfatal
and fatal CVD found amongst all men
with PCa, especially those treated
with endocrine therapy
Van
Hemelrijck
et al [11]
PcBaSE
Sweden
2010 Prospective
cohort
GnRH agonists,
orchiectomy,
antiandrogens, combined
androgen blockade,
medical or surgical ADT
76 601 men with
PCa
<65, 65–74, 75 Nonfatal DVT: 259/17 797 (331/45 958)
PE: 220/17 797 (493/45 958)
All men with PCa at higher risk of
thromboembolic diseases, with
highest risk for those on endocrine
therapy
ADT = androgen deprivation therapy; AMI = acute myocardial infarction; CHD = coronary heart disease; CVD = cardiovascular disease; DVT = deep vein thrombosis; GnRH = gonadotropin-releasing hormone; HF = heart
failure; IHD = ischemic heart disease; MI = myocardial infarction; PCa = prostate cancer; PE = pulmonary embolism; SEER = Surveillance, Epidemiology, and End Results Medicare database; TIA = transient ischemic attack;
UKGPRD = UK General Practice Research Database; VHA = Veterans Health Administration.
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Fig. 3 – (a) Forest plot for the association between gonadotropin-releasing hormone (GnRH) agonists and nonfatal cardiovascular disease (CVD) events; (b) contour-enhanced funnel plot for the association between
GnRH agonists and nonfatal CVD events; (c) forest plot for the association between orchiectomy and nonfatal CVD events; (d) forest plot for the association between antiandrogens and nonfatal CVD events.
CI = confidence interval; CVD = cardiovascular disease; DVT = deep vein thrombosis; GnRH = gonadotropin-releasing hormone; IHD = ischemic heart disease; MI = myocardial infarction; RR = relative risk;
SEER = Surveillance, Epidemiology, and End Results.
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Fig. 4 – Forest plot for the association between gonadotropin-releasing hormone agonists and nonfatal or fatal myocardial infarction.
CI = confidence interval; MI = myocardial infarction; RR = relative risk; SEER = Surveillance, Epidemiology, and End Results.
E U RO P E AN URO L OGY 6 8 ( 2 0 1 5 ) 3 8 6 – 3 9 6 393analysis of RCTs (where CVDwas not the primary end point)
showed that ADTwas associatedwith early onset of fatal MI
in men aged 65 yr or men who had been under treatment
>6 mo compared with those who were not receiving ADT
[36]. A meta-analysis of RCTs comparing GnRH agonists
versus antagonists showed that ADT may be an indepen-
dent risk factor for CVD in men with preexisting CVD [9].
Our results suggest that GnRH agonists and orchiectomy
have similar effects on nonfatal CVD events. Keating et al
previously reported in two different publications that
(1) treatment with GnRH agonists and orchiectomy, com-
paredwith noADT, is positively associatedwith an increased
risk of diabetes, CHD, MI, and sudden cardiac death and that
(2) orchiectomy was not associated with CVD events,
possibly due to small sample sizes [12,13]. In a study by
Jespersen et al, MI or stroke were positively associated with
GnRH agonists but not with orchiectomy [15]. Given that
both treatments lead to castration androgen levels, it is to be
expected that results would be similar with variations
according to the number of patients being analysed, as
[(Fig._5)TD$FIG]
Fig. 5 – Forest plot for the association between gonadotropin-releasing hormo
CI = confidence interval; RR = relative risk.suggested by Keating et al [12,13]. It has been shown that
human heart tissue expresses the GnRH receptor, and an
experimental study on rat heart tissue showed that
stimulation of the cells with GnRH agonists causes changes
in the contractility of the cardiomyocytes [51,52]. Although
most studies on ADT and CVD have found that ADT increases
the risk of having a CVD event, more experimental and
epidemiological studies are needed to differentiate the CV
effects of different types of ADT.
Both indirect and direct biologic mechanisms have been
suggested for the link between ADT and increased risk of CVD.
The main indirect mechanism by which ADT is thought to
increase the risk of CVD is by reducing circulating testosterone
levels [53]. Low levels of androgens have shown to increase
levels of low-density lipoprotein, triglycerides, and insulin, all
defined as components of themetabolic syndrome, which is a
strong risk factor for CVD [54]. In addition to the metabolic
effects of testosterone, it has been proposed that testosterone
may have a protective effect against the development of
atheromatous plaques by causing coronary artery dilation andne agonists and nonfatal or fatal stroke.
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[55]. Normal levels of testosterone have been shown to
decrease the risk of CV events compared with lower
testosterone values [9]. Direct effects are thought to occur
via the immune system. The GnRH receptor has been found to
be expressed on T lymphocytes [56]. These cells are known to
be part of atheromatous plaques, and their activation leads to
interferon-g production and activation of macrophages
causing plaque instability and increasing the risk of
thromboembolic complications [57]. Experimental studies
have shown that GnRH agonists can activate T lymphocytes
and induce their proliferation.However, theseeffectswerenot
observed when using GnRH antagonists [56,58]. These
mechanisms could potentially explain the strong association
we found between GnRH agonists and nonfatal or fatal MI
and stroke. As suggested by experimental studies and the
Albertsen et al meta-analysis [9], other types of ADT, such
as GnRH antagonists, may therefore have fewer adverse
effects on CVD. However, to date no observational data are
yet available to analyse the association between GnRH
antagonists and the risk of CVD.
In contrast to the corroborating findings from RCTs and
observational studies for the association between ADT and
nonfatal CVD, the findings for fatal CVD are less in
agreement. Nguyen et al concluded in their RCT meta-
analysis that ADT does not increase the risk of fatal CVD
[6]. Using data from observational studies, our meta-
analysis showed an increased risk of all MI and stroke
associated with GnRH agonists (including nonfatal and fatal
events), as well as in sensitivity analyses restricting to
studies that explicitly focused on fatal events. Even though
most studies show that ADT has an impact on the risk of
CVD, inconsistent findings for fatal CVD are likely explained
by the differences between the studies analysed, especially
RCTs and observational studies. One has to be aware that
RCTs often do not assess nonfatal events, and some
observational studies do not make a distinction between
fatal and nonfatal events. Most CVD events are nonfatal;
thus it is more difficult for an RCT to find a positive
association, particularly because men enrolled in RCTs are
generally healthier than the general population and will
experience fewer fatal CVD events [19]. Also, as mentioned
previously, RCTs tend to exclude older patients or those
with more comorbidities, whereby the latter may poten-
tially also reflect differences in dietary and lifestyle habits
associated with the risk of CVD [19]. The lower risk of CVD
events amongst healthier younger and RCT patients could
explain the absence of an association observed in these
studies. Furthermore, these RCTs did not take into account a
history of CVD, making it possible that subgroups of men
with PCa with preexisting CVD could have an increased risk
of a fatal CVD associated with ADT [6].
Observational studies are less expensive and easier to
implement than RCTs. When conducted well and based on
large and well-documented databases, the results often
reflect a broader patient population and therefore may be
more applicable to the general population and everyday
clinical practice [59]. Although it has been reported that
observational studies find stronger treatment effects thanRCTs, a more recent publication comparing results between
these types of study designs showed that the estimates of
the treatment effects were similar [20].
It is thus reasonable to assume that the studies included
in this meta-analysis represent general populations
of men with PCa: UK General Practice Research Database;
PcBaSe Sweden, based on the National Prostate Cancer
Register of Sweden; the US Veterans Health Administration;
the Surveillance, Epidemiology, and End Results (SEER)–
Medicare database; and the Danish Cancer Registry.
Nevertheless, an important limitation of observational
studies is the possibility of bias introducedby selection ofmen
toreceive treatment.Menwhoare treatedwithADTmaydiffer
frommenwho are not in ways that are also associated with a
risk for CVD. Although most of the studies included in this
meta-analysis conducted analyses adjusting for observed
confounders, we could only rely on crude event rates because
most studies did not provide sufficient data to allow us to
account for potential confounders in our analyses. In future
studies it would be of interest to add sensitivity analyses
focusedon specific subgroups of patients such as thosewithor
without a history of CVD.
We made every effort to include all relevant publications
available to date through various sources, including grey
literature, and three main online databases. In addition,
clearly defined objective criteria for exposure, outcome, and
other study characteristics were specified a priori. One
limitation of our study is that CVD definitions were not
always available, sowehad to assume theywere comparable
amongst the different studies. The overall results showed a
rather larger amount of heterogeneity as described by the I2
statistic, but the ‘‘remove-one’’ analysis and sensitivity
analyses as well as the direction of individual study findings
suggests that our findings are robust. The funnel plot
indicated that there is no publication bias and that the
heterogeneity is most likely explained by other differences
between the studies: study design and potential differences
in underlying biologic mechanisms due to variety in the
study population and exposure or outcome assessment.
Another limitation is thatwe could notmake a distinction
between patients with and without a history of CVD. This
difference could have shown whether ADT increases even
more the risk of CVD events in a subgroup of patients with
CVD history, as previously suggested by some studies [38]
but not all [60]. Information on when ADT was given
(primary, (neo)adjuvant, or salvage therapy) was not
available, so it was not possible to perform a subgroup
analysis related to the scheduling and duration of ADT.
Limitations reported by the included studies comprise
risk estimate imprecisions due to the small number of
patients experiencing CVD events, incomplete data on
disease stage, prostate-specific antigen and Gleason score,
lack of randomisation, confounding bias, study population
age restrictions, and incomplete data on CVD history.
4. Conclusions
This first meta-analysis analysing observational studies
showed consistent positive associations between ADT,
E U RO P E AN URO L OGY 6 8 ( 2 0 1 5 ) 3 8 6 – 3 9 6 395especially GnRH agonists and orchiectomy, and the occur-
rence of CVD events. This contrast with meta-findings
from RCTs may be due to differences in study design.
However, data from observational studies represent a
broader population with fewer age and comorbidity restric-
tions,whichcan lead tomoreapplicable results to thegeneral
population. The present study supports the need for future
RCTs of PCa patients to include older patients and those with
multiple comorbidities to better reflect the general popula-
tion ofmenwith PCa [19]. The differences observed for GnRH
agonists and orchiectomy need to be further disentangled,
both biologically and epidemiologically.
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